Diabetes
Refine Search
Pharmaceutical
USA-based NGM Biopharmaceuticals has signed a worldwide agreement with health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals to discover and develop novel therapeutics for the potential treatment of type 2 diabetes and other metabolic diseases. 4 January 2013
Pharmaceutical
Danish insulin giant Novo Nordisk (NOVN: NV) revealed on December 15 that the Japanese Ministry of Health, Labor and Welfare has approved the firm's Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes. 27 December 2012
Pharmaceutical
Two US subsidiaries of French drug major Sanofi (Euronext: SAN) have agreed to pay $109 million to resolve allegations that Sanofi US violated the False Claims Act by giving physicians free units of Hyalgan (hyaluronate), a knee injection, in violation of the Anti-Kickback Statute, to induce them to purchase and prescribe the product. 20 December 2012
Pharmaceutical
US drug developer Lexicon Pharmaceuticals (Nasdaq: LXRX) saw its shares leap 9.1% to $2.04 in premarket trading yesterday, as the company announced that the Food and Drug Administration has fast-tracked in its LX1033, an orally-delivered small molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d). 17 December 2012
Pharmaceutical
Once again, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found no added benefit for German independent drugmaker Boehringer Ingelheim and US partner Eli Lilly's (NYSE: LLY) Trajenta (linagliptin; The Pharma Letter January 10), which has been approved since August 2011 to improve blood glucose control in adults with type 2 diabetes. 13 December 2012
Pharmaceutical
Takeda Global Research & Development Center, a unit of Japanese drug giant Takeda Pharma's (TYO: 4502), and Denmark's Lundbeck (LUND: DC) jointly announced that the US Food and Drug Administration has accepted for filing their submission of a New Drug Application for vortioxetine for the treatment of major depressive disorder (MDD) in adult patients. 13 December 2012
Pharmaceutical
Merck Serono, a division of Germany's Merck KGaA (MRK: DE), Germany, and Unite Arab Emirates drug manufacturer Neopharma, announced the first partnership of its kind to locally produce Merck branded medication in the UAE for distribution across the Middle East, reports the Emirates News Agency. 4 December 2012
Pharmaceutical
Global insulin market leader Novo Nordisk (NOV: N) of Denmark revealed this morning that its Ryzodeg (insulin degludec/insulin aspart) has passed the review by the First Committee on Drugs of Japan's Pharmaceutical Affairs. The remaining step in the regulatory process is an approval from the Ministry of Health, Labour and Welfare. 3 December 2012
Pharmaceutical
Global Denmark-based insulin giant Novo Nordisk (NOV: N) yesterday reported data from two Phase IIIb studies showing that a significantly higher number of patients receiving the firm's diabetes drug Victoza (liraglutide) achieved HbA1c levels <7% at any given time point in time (12, 20 and 26 weeks) during the 26 weeks of treatment period compared to sitagliptin or exenatide, the company's major competitors in the diabetes arena, Merck & Co's Januvia and Amylin's Bydureon, respectively. 28 November 2012
Pharmaceutical
The European Medicines Agency said yesterday that it has been formally notified by UK-based Marvel LifeScience Ltd of its decision to withdraw its applications for centralized marketing authorisations for the medicines Solumarv, Isomarv and Combimarv (human insulin), all 100 IU/ml solution for injection. 27 November 2012
Biotechnology
The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major Sanofi's diabetes drug candidate Lyxumia (lixisenatide; The Pharma Letter November 19), its expected US New Drug Application filing next month and the potential European Union approval in first-quarter 2013, create a likely hat trick of positive catalysts for Denmark's Zealand Pharma (Nasdaq OMX: ZEAL), which discover the GLP-1 receptor agonist, say analysts at Edison Equity Research. 23 November 2012
Pharmaceutical
Rosiglitazone, the active ingredient of GlaxoSmithKline's diabetes drug Avandia, has shown promise as a way to improve cognitive performance in some people with Alzheimer's disease. 21 November 2012
Generics
Brazil has submitted to Ukrainian authorities $4.5 billion worth of investment proposals. "We want to build the mini-tractors production plant in Ukraine as well as purchase shipbuilding and pharmaceutical manufacturing technology," said Jose Barouki, director of trade and investment company Daruvar SA during the Ukrainian investment roadshow in Sao Paulo, Brazil. 19 November 2012
Biotechnology
There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) following its monthly meeting on human use marketing authorization applications. 19 November 2012
Biotechnology
Bangalore, India-based biotechnology firm Biocon (BSE: 532523) has entered into an option agreement with US drug major Bristol-Myers Squibb (NYSE: BMY) for Biocon's IN-105, a prandial oral insulin product candidate. Currently, there are no insulin tablets available and patients with diabetes who need insulin must inject it. 19 November 2012
Pharmaceutical
There was good news for AstraZeneca (LSE: AZN) and Bristol-Myers Squibb (NYSE: BMY), with the European Commission approval of Forxiga (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union. 15 November 2012
Pharmaceutical
The global diabetes drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 9.7% through to 2015, with the industry set to hit a value of $98.4 billion by 2018, according to a new report added to the offering of Companies and markets. 14 November 2012
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany has found the formulation patent protecting its schizophrenia drug Seroquel XR (quetiapine fumarate) prolonged-release tablets - marketed as Seroquel Prolong in Germany - to be invalid. 14 November 2012
Pharmaceutical
America's biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the USA affected by diabetes. The medicines in development - all in either clinical trials or under review by the Food and Drug Administration - include 32 for type 1 diabetes, 130 for type 2 and 64 for diabetes-related conditions, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA). 13 November 2012
Pharmaceutical
US drug giant Merck & Co (NYSE: MRK) says that the New Drug Application for suvorexant, the company's investigational insomnia drug candidate, has been accepted for standard review by the US Food and Drug Administration. If approved, suvorexant would be the first in a new class of medicines, called orexin receptor antagonists, for use in patients with difficulty falling or staying asleep. 9 November 2012
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze